Bivalent Subtype C gp120/MF59

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV Infections

Phase 1

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

CompletedNCT03122223

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2018-01-16End: 2020-07-30Updated: 2023-03-14

Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine

CompletedNCT03284710

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2017-06-19End: 2019-12-12Updated: 2026-07-24

Phase 2

Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa

CompletedNCT02968849

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2016-10-26End: 2021-11-16Updated: 2026-05-04

Related Papers

ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost

PLOS Global Public Health2025-04-11

A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials

Emerging Microbes & Infections2025-04-071 citations

Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120.

2024-08-014 citations

Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial

PLoS Medicine2024-03-198 citations

The Question of HIV Vaccine: Why Is a Solution Not Yet Available?

Journal of Immunology Research2024-01-0112 citations

Data quality in an HIV vaccine efficacy clinical trial in South Africa: through natural disasters and with discipline

BMC Medical Research Methodology2023-06-24

Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk

The Journal of Infectious Diseases2022-06-2747 citations

Participants' characteristics and motivations to screen for HIV vaccine and monoclonal antibody trials in KwaZulu-Natal, South Africa.

2021-12-113 citations

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults

New England Journal of Medicine2021-03-24220 citations

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.

2019-10-0738 citations

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial

Journal of Clinical Investigation2019-09-3035 citations